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Abstract. Aim: The primary aim of the study was to assess
the association between risk of recurrence and HER2
equivocal gene status through immunohistochemistry in
patients with early breast cancer. Patients and Methods: We
retrospectively analyzed clinical and pathological data of
455 consecutive patients with early breast cancer (BC) who
were HER2+ and had a HER2/CEP17 ratio <2.0, who
underwent surgery at the European Institute of Oncology
after 2007. The role of HER2/CEP17 ratio on recurrence-
free survival was assessed with univariate and multivariate
Cox regression models. Results: We found no significant
association between risk of recurrence and HER2 equivocal
testing in patients with early breast cancer. In subgroup
analysis, a significant interaction between HER2/CEP17
ratio and nodal involvement was observed (p=0.02).
Conclusion: Patients with HER2 equivocal status have no
significantly higher risk of recurrence. 
Overexpression of the human epidermal growth factor
receptor type 2 (HER2) occurs in approximately 15% to 20%
of invasive breast cancers and is associated with poor clinical
outcome (1-3). Trastuzumab, a humanized monoclonal
antibody that binds HER2, improves the outcomes for
patients with HER2-positive breast cancer (BC). Four phase
3 randomized trials involving more than 8,000 patients
showed that trastuzumab decreased the risk of recurrence by
approximately 50% and improved overall survival (4-7). By
applying immunohistochemistry (IHC) to assess protein
overexpression, BC can be classified into two major groups:
HER2-positive (score 3+) BC and HER2-negative (score 0
and 1+) BC. However, up to 18% of all newly-diagnosed BC
have an equivocal HER2 expression (score 2+) (8). In this
group, HER2 positivity must be confirmed by fluorescence
in situ hybridization (FISH). BC often shows heterogeneity
in HER2 overexpression and ampliﬁcation, with only a
fraction of tumor cells being HER2-positive. Thus far, only
patients with HER2 positivity, defined as either 3+ by IHC
or FISH amplified defined as a HER2 gene to chromosome
17 (HER2/CEP17) ratio ≥2.0, are suitable to receive
trastuzumab treatment. Limited data are available on clinico-
pathological significance of HER2 equivocal status and on
the prognostic role HER2 2+ and FISH test with a
HER2/CEP17 ratio <2.0 in patients with early breast cancer.
We designed the present study to provide a definitive portrait
of this controversial category of breast cancers. The primary
aim of the study was to assess the prognostic role of
equivocal IHC HER2 status with a HER2/CEP17 ratio <2.0
in patients with early breast cancer. 
Materials and Methods
We retrospectively analyzed data from 455 consecutive early BC
patients with HER2+ and HER2/CEP17 ratio <2.0 who underwent
surgery after 2007. The European Institute of Oncology ethical
committee approved the present analysis. In the study we included
tumor samples from patients who gave their consent to use their
biological samples for research purpose. HER2 status was assessed
according to 2013 recommendations of American Society of
Clinical Oncology and College of American Pathologists
guidelines. We used the HercepTest preparation kit (Dako,
Glostrup, Denmark) and scored the results according to FDA/EMA
recommendations; therefore, score 2+ cases were those exhibiting
mild to moderate complete membranous staining in at least 10% of
cells. IHC data on estrogen receptor (ER) and progesterone
receptor (PR) expression and on proliferation index (Ki-67) were
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obtained from the original pathology reports. FISH was performed
according to the manufacturer’s instructions with probes for HER2
and CEP17 (Abbott Molecular Diagnostics, Abbott Park, IL, USA),
as described previously. For analysis, 10 invasive areas on each
slide were selected and automatically acquired at ×40 with the
motorized Metafer scanning system (Carl Zeiss MetaSystems
GmbH, Jena, Germany) and Axio Imager epifluorescence
microscope (one focus plane for DAPI [4’,6-diamidino-2-
phenylindole] and 13 focus planes for green and red spots).
PathVysion V2 software (MetaSystems Hard & Software GmbH,
Altlußheim, Germany) (FDA approved) was used to automatically
analyze HER2 and CEP17 probes. A range of 300-800 cells was
examined. Results were reviewed by three pathologists and scored
according to both FDA/EMA recommendations (7, 8) and
ASCO/CAP guidelines 2013 for dual-signal assay analyses. In
addition, we also simulated the scoring for the single-signal assay
by taking into account HER2 gene counting only. In the latest
ASCO/CAP 2013 guidelines, HER2 gene counting is the only
parameter evaluated for single-probe ISH and is also integrated into
the evaluation of the results of the HER2/CEP17 ratio for dual-
signal ISH. The distribution of FISH ratio is reported in Figure 1.
Heterogeneity was defined according to the supplemental material
shown in the ASCO/CAP 2013 guidelines. Since the HER2/CEP17
ratio was positively skewed, it was analyzed after logarithmic
transformation. The association between HER2/CEP17 ratio and
other known prognostic factors was evaluated by using linear
regression. The role of HER2/CEP17 ratio on recurrence-free
survival was assessed with univariable and multivariable Cox
regression models.
Results
Patients characteristics are reported in Table I. Fifty-one
percent were node negative, 51% were postmenopausal, 92%
had ER-positive BC and 85% had Ki-67 ≥14%. The overall
geometric mean of HER2/CEP17 ratio was 1.25
(95%CI=1.22-1.27). A highly significant positive relationship
between HER2/CEP17 ratio and Ki-67 was observed
(p<0.001). Four-hundred patients (80%) received an endocrine
treatment (99 patients in combination with chemotherapy) as
adjuvant treatment. Thirty-six patients received only
chemotherapy. At a median follow-up of 2.7 years, 40 tumor
recurrences were observed [15 locoregional events and 25
distant metastases]. Overall, in patients with IHC HER2 2+
early BC HER2/CEP17 ratio was not associated with the risk
of recurrence, both at univariate (Figure 2) and multivariate
analysis. In an explorative subgroup analysis, a significant
interaction between HER2/CEP17 ratio and nodal involvement
was observed (p=0.02). Among patients with node-negative
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Table I. Patients’ characteristics.
Variable Levels N (%) HER2/CEP 17 ratio p-Value
Geometric Mean (95% CI)
All patients 455 (100) 1.25 (1.22-1.27)
Age class <35 22 (4.8) 1.20 (1.12-1.29) 0.19
35-50 197 (43.3) 1.22 (1.19-1.26)
51-65 178 (39.1) 1.27 (1.23-1.31)
>65 58 (12.7) 1.29 (1.22-1.36)
Menopausal status Pre-menopausal 220 (48.4) 1.21 (1.18-1.24) 0.0032
Post-menopausal 235 (51.6) 1.28 (1.25-1.32)
Histology Ductal 384 (84.4) 1.25 (1.23-1.28) 0.27
Others 71 (15.6) 1.22 (1.16-1.28)
pT 1 244 (53.6) 1.25 (1.22-1.29) 0.049
2 172 (37.8) 1.26 (1.22-1.30)
3-4 39 (8.6) 1.15 (1.09-1.22)
No. of positive lymph nodes None 236 (51.9) 1.25 (1.21-1.28) 0.32
1-3 141 (31) 1.26 (1.22-1.31)
4+ 78 (17.1) 1.21 (1.16-1.26)
Grade Unknown* 8 (1.8) 1.14 (1.02-1.28)
1-2 279 (61.3) 1.23 (1.20-1.26) 0.051
3 168 (36.9) 1.28 (1.24-1.32)
ER/PgR PgR=0 and ER = 0 35 (7.7) 1.26 (1.16-1.36) 0.64
0<PgR<50 or 0<ER<50 161 (35.4) 1.26 (1.22-1.30)
ER>=50 and PgR >=50) 259 (56.9) 1.24 (1.21-1.27)
Ki-67 <14% 69 (15.2) 1.15 (1.11-1.21) 0.0008
>=14% 386 (84.8) 1.26 (1.24-1.29)
PVI Absent 272 (59.8) 1.23 (1.20-1.26) 0.15
Moderate/Focal 94 (20.7) 1.28 (1.23-1.34)
Diffuse 89 (19.6) 1.26 (1.21-1.32)
disease, those with high HER2/CEP17 ratio (>1.25, i.e. the
overall observed geometric mean] were at higher risk of
recurrence as compared to patients with low HER2/CEP17
ratio (adjusted HR=4.8, 95%CI=1.3-17.8).
Discussion
This study reports data from a large, mono-institutional cohort
of patients with HER2 equivocal early breast cancer. Whether
patients with IHC HER2 equivocal tumors should receive
targeted therapy remains a challenging question for
oncologists, particularly as reporting guidelines evolve. A
clinical note in 2011 regarding ASCO/CAP guideline
recommendations on HER2 testing stated that the expert panel
did not recommend withholding treatment for patients with an
equivocal HER2 test whose results fell within ranges for
eligibility in the first generation adjuvant HER2-targeted trials.
The 2013 ASCO/CAP guidelines maintain this caveat, giving
latitude to oncologists to consider HER2-targeted therapy for
patients with equivocal HER2 test results, even after reflex
testing with an alternative assay. Clearly, there is a need to
further examine this group of tumors to obtain optimal
prognostic and treatment determinations. A randomized phase
III trial of adjuvant therapy comparing chemotherapy alone (6
cycles of docetaxel plus cyclophosphamide or 4 cycles of
doxorubicin plus cyclophosphamide followed by weekly
paclitaxel) to chemotherapy plus trastuzumab in women with
node-positive or high-risk node-negative HER2-Low invasive
breast cancer is actually ongoing (study B47 of the National
Surgical Adjuvant Breast and Bowel Project [NSABP] study
group). Eligibility includes node positive or high-risk node-
negative BC patients with HER2 IHC 1+ or 2+ scores, but
non-amplified by FISH; 3,260 patients will be enrolled. A very
limited number of studies assessed the role of HER2 equivocal
status in early breast cancer (9). The largest series analyzed
was published by Sapino et al. (9). A cohort of 957
immunohistochemistry-evaluated HER2-equivocal cases was
analyzed by dual-color FISH. The results were assessed
according to U.S. Food and Drug Administration (FDA) and
European Medicines Agency (EMA) guidelines and American
Society of Clinical Oncology (ASCO) and College of
American Pathologists (CAP) 2007 and 2013 guidelines for
dual- and single-signal in situ hybridization (ISH) assays.
HER2 amplification varied from 15% (ASCO/CAP 2007
HER2/CEP17 ratio) to 29.5% (FDA/EMA HER2 copy
number). According to the ASCO/CAP 2013 interpretation of
the dual-signal HER2 assay, ISH-positive carcinomas
accounted for 19.7%. 
In contrast with the ASCO/CAP 2007 ratio, this approach
labeled as positive all 32 cases (3.34%) with a HER2/CEP17
ratio <2 and an average HER2 copy number ≥6.0 signals per
cell. In contrast, only one case showing a HER2 copy
number <4 but a ratio ≥2 was diagnosed as positive. Authors
concluded that the ASCO/CAP 2013 guidelines seem to
improve the identification of HER2-positive carcinomas (9).
In our study, despite the samples size in not similar, we
provide data on outcome of patients with HER2 equivocal
status. Our results do not support indication to trastuzumab
in patients with equivocal IHC HER2 early breast cancer. In
summary, in our series HER2 equivocal BC represent a
subgroup of high-grade estrogen receptor-positive tumors
with higher proliferative activity. The B47 NSABP study will
assess whether the addition of trastuzumab to chemotherapy
improves invasive disease-free survival [IDFS] in this group
of patients. 
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Figure 1. Distribution of FISH Ratio. 
Figure 2. Effect of HER2/CEP17 ratio, treated as a continuous variable
in a univariable Cox model, on the hazard ratio (HR) of tumor
recurrence. The reference HER2/CEP17 ratio used for the computation
of HR is the overall geometric mean (1.25).
Conclusion 
We found no significant association between risk of
recurrence and HER2 equivocal testing in patients with early
breast cancer. In subgroup analysis, a significant interaction
between HER2/CEP17 ratio and nodal involvement was
observed (p=0.02). Patients with HER2 equivocal status
have no significant risk of recurrence. In our analysis IHC
HER2 2+ status with HER2/CEP17 ratio <2.0 has no impact
on prognosis of patients with early breast cancer. 
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